Loading...
Keywords
Last Name
Institution

Connection

Search Results to J. Steven Leeder

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Leeder, J. Steven

PropertyValue
keywords Pediatric Precision Therapeutics
research overview In his former role as Director of the Division of Clinical Pharmacology and Therapeutic Innovation at Children’s Mercy Dr. Leeder led a program consisting of multidisciplinary teams of researchers with expertise in analytical chemistry, drug biotransformation, gene regulation, pharmacogenomics, and pharmacokinetics to investigate variability in medication response in children. An important component of the program was to provide an environment in which trainees and early career faculty members from diverse backgrounds could develop as independent investigators in their areas of research interest. These research interests generally are closely aligned with their clinical expertise with the goal of implementing precision therapeutics in their clinical subspecialties to benefit the patients they serve. Currently, Dr Leeder is Executive Director (Interim) of the Children’s Mercy Research Institute and leads the Precision Therapeutics Area of Emphasis. The Precision Therapeutics initiative extends the Division of Clinical Pharmacology's emphasis on developing individuals to a more institutional level by providing support to pediatric subspecialties interested in adding precision therapeutics to their portfolio of research programs. In this way the program serves as a model of integrated research that will extend throughout the CMRI. Over the years, Dr. Leeder's research interests in pediatric pharmacogenetics and the ontogeny of drug biotransformation pathways during growth and development have coalesced into the GOLDILOKs initiative: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids. Originally funded as one of four Specialized Centers for Research in Pediatric Developmental Pharmacology supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development, "GOLDILOKs" now represents a conceptual approach to better understanding factors contributing to variability in drug disposition and response and using that information to make the use of medications safer and more effective in children of all ages. Dr. Leeder is also co-PI, with Dr. Mario Castro (KUMC), of the Frontiers Clinical and Translational Science Institute at the University of Kansas.

One or more keywords matched the following items that are connected to Leeder, J. Steven

Item TypeName
Concept Drug Therapy
Concept Drug Therapy, Combination
Concept Therapeutic Equivalency
Concept Genetic Therapy
Concept Treatment Outcome
Concept Opiate Substitution Treatment
Concept Molecular Targeted Therapy
Academic Article The challenges of delivering pharmacogenomics into clinical pediatrics.
Academic Article Developmental pharmacology--drug disposition, action, and therapy in infants and children.
Academic Article Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Academic Article The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response.
Academic Article Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.
Academic Article Safety of lidocaine-prilocaine cream in the treatment of preterm neonates.
Academic Article Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.
Academic Article Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children.
Academic Article Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Academic Article VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Academic Article Glucocorticoid genes and the developmental origins of asthma susceptibility and treatment response.
Academic Article Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone.
Academic Article Acetaminophen overdose with therapeutic intent.
Academic Article Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.
Academic Article Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Academic Article Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.
Academic Article Acetaminophen intoxication during treatment: what you don't know can hurt you.
Academic Article Glucagon therapy for beta-blocker overdose.
Academic Article Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier?
Academic Article Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Academic Article Considerations for Implementing Precision Therapeutics for Children.
Academic Article Optimization of gentamicin therapy in very low birth weight infants.
Academic Article In: Antimicrobial Therapy in Infants and Children. Koren G, Gold R and Prober C, Ed
Academic Article In: Problems in Pediatric Drug Therapy, Fourth Edition, Pagliaro LA and Pagliaro AM (Eds)
Academic Article Principles of Drug Administration in Children Receiving Renal Replacement Therapy Second Edition
Academic Article In Biochemical and Molecular Basis of Pediatric Disease, 4th Ed., Wong E, Bennett M, and Dietzen D, eds
Academic Article In: Textbook of Pediatric Rheumatology, Seventh Edition, Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, (Eds)
Academic Article Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data.
Grant Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
Grant Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions
Award or Honor Receipt Rawls-Palmer Progress in Medicine Award
Award or Honor Receipt Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics
Academic Article Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Grant Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
Grant Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology
Grant Effect of Obesity on Pantoprazole Pharmacokinetics and Pharmacodynamics in Children
Academic Article Identifying Effective Treatments for Dystonia in Patients With Cerebral Palsy: A Precision Therapeutics Approach.

Search Criteria
  • Therapeutics